Evidence map›Paper›PMID 37895310›Full record

ArticleGenes2023

Systematic Pan-Cancer Analysis Reveals X-C Motif Chemokine Receptor 1 as a Prognostic and Immunological Biomarker.

Likun Cui, Liye Zhu, Jie Chen, Chunzhen Li, Yizhi Yu, Sheng Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Likun CuiNational Key Laboratory of Medical Immunology and Institute of Immunology, Naval Medical University, Shanghai 200433, China.ORCID 0000-0002-3950-0358
Liye ZhuNational Key Laboratory of Medical Immunology and Institute of Immunology, Naval Medical University, Shanghai 200433, China.
Jie ChenNational Key Laboratory of Medical Immunology and Institute of Immunology, Naval Medical University, Shanghai 200433, China.
Chunzhen LiNational Key Laboratory of Medical Immunology and Institute of Immunology, Naval Medical University, Shanghai 200433, China.
Yizhi YuNational Key Laboratory of Medical Immunology and Institute of Immunology, Naval Medical University, Shanghai 200433, China.
Sheng XuNational Key Laboratory of Medical Immunology and Institute of Immunology, Naval Medical University, Shanghai 200433, China.
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemokines and their receptors play an important role in immune monitoring and immune defense during tumor growth and metastasis. However, their prognostic roles in pan-cancer have not been elucidated. In this work, we screened all chemokine receptors in pan-cancer and discovered X-C Motif Chemokine Receptor 1 (

Indexed as

CD8-Positive T-LymphocytesNeoplasmsBiomarkersHumansPrognosisReceptors, ChemokineReceptors, G-Protein-CoupledTumor MicroenvironmentBiomarkersReceptors, ChemokineReceptors, G-Protein-CoupledXCR1 protein, humanimmune infiltrationpan-cancerprognosisXCR1

Identifiers

PMID37895310
PMCPMC10606244
OpenAlexW4387772565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.